We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Melanomas Are "Born to Run”

By Biotechdaily staff writers
Posted on 13 Oct 2005
Cancer researchers have learned why melanomas are so aggressively malignant while other types of cancer may require years of development before being able to metastasize.

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) found that a gene called SLUG (named after the embryo shape that the mutated gene causes in fruit flies), which is turned off in normal adult tissue, is activated in melanomas. More...
SLUG is a leftover from the neural crest developmental stage when primal melanocytes are formed. Cells with active SLUG are readily able to spread throughout the body.

When melanoma cells were genetically engineered to lack SLUG activity, they were unable to metastasize after being transplanted into susceptible mice. Detailed findings were published in September 4, 2005, online edition of Nature Genetics.
"Other cancers need to learn how to spread, but not melanoma,” said senior author Dr. Robert Weinberg, professor of biology at MIT. "Now, for the first time, we understand the genetic mechanism responsible for this.”



Related Links:
Massachusetts Institute of Technology

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Electrolyte Analyzer
BKE-B
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.